Abstract Lung immaturity is the major cause of morbidity and mortality in premature infants, especially those born <28 weeks gestation. Proper lung development from 23-28 weeks requires coordinated cell proliferation and differentiation. Infants born at this age are at high risk for respiratory distress syndrome (RDS), a lung disease characterized by insufficient surfactant production due to immaturity of the alveoli and its constituent cells in the lung. The ErbB4 receptor and its stimulation by neuregulin (NRG) plays a critical role in surfactant synthesis by alveolar type II epithelial cells. In this review, we first provide an introduction to normal human alveolar development, followed by a discussion of the neuregulin and ErbB4-mediated mechanisms regulating alveolar development and surfactant production.
Introduction
More than 10 % of infants are born prematurely, before the 37th week of pregnancy. Prematurity exposes the infant to risks of pulmonary, cardiovascular, nutritional and neurologic complications. The incidence and severity of these complications increases with the degree of prematurity. For example, extremely low birth weight infants (defined as ≤28 weeks gestation or ≤1,000 g birth weight) have a 50 % risk of neurological morbidity and up to an 80 % risk of developing respiratory distress syndrome (RDS) and subsequently bronchopulmonary dysplasia (BPD) as a result of lung immaturity. Proper lung development from 23-28 weeks requires coordinated distal airway epithelial cell proliferation and differentiation. One of the key differentiated functions of lung alveolar epithelial cells is their ability to produce surfactant. Surfactant synthesis in preparation for birth is a crucial component of fetal lung development (Langston et al. 1984) , and insufficient surfactant production by immature type II cells leads directly to RDS. Despite the beneficial effects of prenatal glucocorticoids and postnatal surfactant replacement therapies, RDS remains a significant cause of morbidity and mortality in premature infants (Andreeva et al. 2007 ), (Jobe et al. 1993) . To treat existing RDS, different clinical interventions such as oxygen therapy in the first week of life have been used. Early oxygen exposure can adversely impact lung development, creating the clinical syndrome of BPD (Kraling et al. 1999 ), a common complication of pre-term birth and early oxygen treatment. BPD is characterized by perturbations to lung structure that include reduced alveolar number, thickened septa, and a simplified pulmonary microvascular network. In this review we examine the biological and molecular basis of surfactant production, focusing on neuregulin (NRG) stimulation of the ErbB4 receptor and subsequent downstream signaling events.
Fetal lung development
Lungs of mammals develop in well described stages: in temporal order they are called embryonic, pseudoglandular, canalicular, saccular and alveolar stages (Fig. 1) . In the embryonic stage the primordial lung forms as a tubular diverticulum from the embryonic foregut. During the pseudoglandular stage the epithelial tubes undergo successive stages of branching, invading the surrounding mesenchyme and forming the arboreal (tree-like) airway structures. This occurs during 5-17 weeks of pregnancy in humans and produces a glandular appearance in microscopic cross sections. During the canalicular stage (16-26 weeks) further differentiation of the epithelium, the future gas-exchange region, and widening of the prospective parenchymal air spaces take place. Moreover, epithelial cells in the most distal tubules begin to differentiate into type I and type II cells, and the synthesis of surfactant in type II cells and its storage in lamellar bodies begins. The following saccular stage (24-38 weeks) is characterized by increased lung parenchymal growth and augmentation of air space volume through the development of saccules budding off from the most distal airways. These saccules contain the type I and II epithelial cells. Saccules further develop into alveoli during the alveolar stage with the formation of secondary septa separating the alveoli. The saccules and alveoli are the sites of gas exchange in the lung. The alveolar stage begins at 36 weeks of pregnancy and lasts up to 3 years after birth. Alveolarization enables humans to multiply their gas exchange area 20-fold between birth and adulthood (Zeltner and Burri 1987) , (Burri 1974) , (Burri 1985) , (Burri and Moschopulos 1992) , (Burri 2006) .
Pulmonary surfactant
Lung surfactant is crucial for gas exchange as it prevents alveolar collapse by reducing surface tension caused by liquid and tissue surface forces. Surfactant is a surface active substance produced in the alveoli by type II epithelial cells. It is a complex mixture of phospholipids, proteins and neutral lipid. The components are synthesized in type II epithelial cells, packaged in lamellar bodies within the type II cells and secreted into the alveolar space by exocytosis. The developmental control of surfactant synthesis requires complex communications between mesenchyme and adjacent type II epithelial cells (Smith 1979) .
Surfactant consists of 90 % lipids and 10 % proteins. Of these lipids 90 % are phospholipids consisting mainly of phosphatidylcholine (70 %) with much smaller amounts of phosphatidylglycerol (12 %) and phosphatidylethanolamine (6 %). These phospholipids are responsible for the surface active quality of surfactant. Disaturated phosphatidylcholine, which has two saturated fatty acids instead of one saturated and one unsaturated fatty acid, makes up 65 % of total phosphatidylcholine and is the major surface active component of lung surfactant. The remaining 10 % of lipids are neutral lipids, mainly cholesterol (Clements 1977) , (Possmayer et al. 1984) . The protein fraction of surfactant is about 10 % by weight of surfactant. Its composition is also highly complex. Serum proteins represents 50 % of the protein content. The remaining fraction is composed of four apolipoproteins, termed surfactant proteins A (SP-A), B (SP-B), C (SP-C) and D (SP-D). Each of these surfactant proteins confers specific biological functions that aid in reducing surface tension in the alveolus (Fehrenbach 2001) .
Lung surfactant has important functions in addition to its surface tension-lowering properties. The surfactant proteins SP-A and SP-D are immunologically important in pulmonary host defense. Surfactant also has an important role in transport of pulmonary secretions, and in protection against oxygen radicals (Crouch and Wright 2001) . However, SP-B and SP-C are thought to play primary roles in reducing surface tension and are known targets for NRG-stimulated activation of the ErbB4 receptor, and thus are described in more detail below.
Surfactant protein B
SP-B is a small, highly hydrophobic protein with molecular weight of 8 KDa. The mature protein is derived from an initial pro-protein through several proteolytic processing events. Mature SP-B is rich in cysteine residues, which stabilizes the SP-B three-dimensional structure with the help of one intermolecular and three intramolecular disulfide bonds. The SP-B Fig. 1 Stages of Lung Development in Humans. The timeline of lung development during human embryonic and early postnatal development is shown gene is encoded on murine chromosome 6 and consists of 11 exons and 10 introns, accompanied by the promoter-enhancer consensus sequence (Margana and Boggaram. 1996) , (Pryhuber. 1998 ). This gene is expressed in a cell/tissue specific manner by alveolar type II and bronchiolar (Clara) epithelial cells of the lung (Phelps and Floros. 1988) . Its major role is to enhance the surface tension reducing properties of surfactant through interaction with the phospholipid monolayer on the alveolar air-liquid interface. SP-B coordinates the insertion of surfactant phospholipids into the surface film and stabilizes it. Furthermore it influences the structure of phospholipid bilayers (Pryhuber 1998) , (Weaver and Conkright 2001) , (Whitsett and Glasser 1998) . SP-B participates in the formation of tubular myelin structure. The inherited absence of SP-B causes lack of proper SP-C protein processing, failure of type II cells to form lamellar bodies, and lack of alveolar surfactant activity, leading to severe respiratory failure and death in newborns. Thus, SP-B is of vital importance in lung surfactant pathobiology.
Surfactant protein C SP-C is the smallest of all surfactant proteins, 6 KDa. Like SP-B, the mature SP-C is processed from a pre-pro-protein in several proteolytic events. Processing is dependent on adequate intracellular levels of mature SP-B. Two-thirds of the mature protein structure is an alpha-helix which is extremely hydrophobic and can insert into a lipid monolayer. SP-C accelerates the insertion of phospholipids into the lipid monolayer and therefore influences the structure of phospholipids in monolayer. Like SP-B, SP-C is crucial for surface dynamics within the terminal air space and the reduction of surface tension (Hamm et al. 1996) . Mutations in the SP-C gene that cause reduced or abnormal SP-C protein are associated with several forms of childhood interstitial pneumonitis.
ErbB receptors
ErbB receptors control cell proliferation and cell differentiation in many cells and tissues of epithelial, mesenchymal and neuronal origin (Nielsen 1989) , (Dammann et al. 2003) , (Gassmann et al. 1995) , (Sardi et al. 2006 ). The ErbB receptors comprise a family of four transmembrane tyrosine kinase receptors ErbB1 (Epidermal Growth Factor Receptor, EGFR), ErbB2, ErbB3 and ErbB4 (Fig. 2) . ErbB1, ErbB3 and ErbB4 receptors have a cysteine-rich extracellular ligand-binding region that is connected to a cytoplasmic tyrosine kinase domain via a single transmembrane-spanning region. Binding of a specific ligand leads to ErbB receptor homo-or heterodimerization and activation (Jones et al. 1999) .
Dimerization of ErbB receptors causes a conformational change of intracellular components, producing transactivation of the dimerization pair by autophosphorylation of the carboxyterminal tyrosine residues (Olayioye et al. 2000) . As there are various ligands of ErbB receptors and all possible dimer pair combinations of ErbB receptors may form, ErbB receptors are able to initiate multiple different biologic signals. This allows ErbB receptors to play significant roles in diverse organ systems during development and maturation including the lung, heart and central nervous system (Dammann et al. 2003) , (Lemmon and Schlessinger 1998) , (Lee et al. 1995) , (Muthuswamy et al. 1999) .
ErbB receptor ligands are categorized into specific groups that bind 1) EGFR only, 2) ErbB3 or ErbB4, or 3) EGFR or ErbB4. Although ErbB specific ligands induce different biological signals when binding to ErbB receptors, they all have in common one or more EGF-like domains that determine binding specificity (Hynes and Lane 2005) , (Muraoka-Cook et al. 2008) . From the EGF family, only 10 have been identified as ligands of the ErbB receptor family: EGF, Transforming Growth Factor alpha (TGFalpha), amphiregulin (AR), heparin-binding Epidermal Growth Factor (HB-EGF), betacellulin (BTC), epiregulin, epigen and NRG. EGF, TGF-alpha and AR bind to ErbB1 only whereas BTC, EPR and HB-EGF, show dual specificity to ErbB1 and ErbB4. Neuregulin-1 (NRG-1) and neuregulin-2 (NRG-2) bind to ErbB3 and ErbB4, while in contrast neuregulin-3 (NRG-3) and neuregulin-4 (NRG-4) bind to ErbB4 only. ErbB2 lacks the EGF-like ligand binding domain and no ErbB2 ligands have been discovered. However, ErbB2 serves as a prominent heterodimerization partner for other ErbB receptors (Karunagaran et al. 1996) . Likewise, ErbB3 lacks a complete intrinsic tyrosine kinase domain, thus preventing signal transduction and requiring heterodimerization with other members of the ErbB family for signaling. Fig. 2 ErbB Receptors. There are 4 members of the ErbB receptor family, all of which are transmembrane tyrosine kinase receptors. All except ErbB2 are ligand activated receptors. ErbB receptors signal through canonical pathways including PI3 kinase, phospholipase C, and ras. Erbb4 and its activating ligand neuregulin (NRG) are important regulators of alveolar epithelial type II cell maturation and surfactant production. Erbb4 is unique because can also signal via a pathway that involves two separate cleavage processes and subsequent nuclear localization (see Fig. 3) The main signaling pathways activated by ErbB receptors are the mitogen activated protein kinase (MAPK), phospholipase C gamma and phosphatidylinositol 3-kinase (PI3K)-AKT pathways (Hynes and Lane. 2005) . A novel signaling mechanism for ErbB4 involving proteolytic cleavage and nuclear transport has recently been characterized and will be described in more detail in the next section.
NRG and the ErbB receptors are important in normal development of the lung (Nielsen 1989) , (Dammann et al. 2003) . The generation of surfactant synthesis during lung development requires communication between the mesenchyme and adjacent type II epithelial cells (Smith 1979) . It is well-established that NRG-1β is secreted by fetal lung fibroblasts and activates the ErbB4 receptor on type II cells to promote the initiation of surfactant synthesis (Dammann et al. 2003) . ErbB4 heterodimers and/or homodimers are crucial for regulation of surfactant phospholipid metabolism and cell proliferation in both fetal and adult lungs (Huang et al. 2012) , (Liu et al. 2010) , (Liu et al. 2009 ). In the fetus, ErbB4 is found in the highest concentrations in brain and heart; however, there are also significant levels in epithelia and mesenchyme of the respiratory tract ). The vital role of ErbB4 for lung development was first demonstrated by the impaired fetal surfactant synthesis that resulted from down regulation of ErbB4 ). Further studies using a transgenic mouse showed that pulmonary ErbB4 deletion caused delayed SP-B production during fetal development and a hyperactive airway system with alveolar simplification in neonates and adults which is comparable to the pathology seen in preterm infants with BPD (Purevdorj et al. 2008) . Previous data from the Nielsen laboratory showed that ErbB4 is present in the nucleus of fetal lung type II cells in culture (Liu et al. 2009 ).
The ErbB4 receptor is unique among the other ErbB receptors in that it can undergo proteolytic processing after NRG binding to enter the nucleus to participate in regulating gene transcription ( Fig. 3 ; Sardi et al. 2006) . In the standard model of ErbB4 proteolytic processing for signal transduction, NRG binding induces ErbB4 cleavage at the cell membrane in two steps: first, by TACE (tumor necrosis factor-alpha converting enzyme) and second by gamma secretase. TACE, a member of the ADAM family of metalloproteases, first cleaves the ErbB receptor at the membrane-spanning region and releases the ectodomain of ErbB4. The remaining ErbB4 fragment is then cleaved by gamma secretase at the inner membrane. This cleavage leads to the release of the 80 KDa intracellular domain fragment (4ICD) (Carpenter 2003) , (Lee et al. 2002) , (Ni et al. 2001) , (Rio et al. 2000) . Once cleaved, the 4ICD fragment associates with at least one chaperon protein, for example Yes associated protein (YAP), to move to the nucleus where it regulates gene transcription (Omerovic et al. 2004 ). 4ICD has an intrinsic nuclear localization signal which facilitates transfer into the nucleus (Williams et al. 2004 ). Cellular responses to 4ICD activated gene expression include proliferation, cell cycle arrest, apoptosis, and cell differentiation (Jones et al. 1999) , depending on the cell type. Nuclear localization of ErbB4 is the preferred mechanism of ErbB4 signaling in at least one significant regulatory process during development, namely, controlling the fate of neuronal precursor cells in the developing brain. (Sardi et al. 2006 ).
Neuregulin (NRG)
Both the canonical and non-canonical (ie, nuclear localization) ErbB4 signaling pathways are initiated by the growth factor peptide neuregulin. This ligand is produced by fetal lung fibroblasts from which it is released to act on fetal type II cells. It reproduces most, if not all, of the activities of what was originally termed fibroblast pneumocyte-factor, the communicating fibroblast substance which induces type II epithelial cell differentiation and surfactant synthesis (Dammann et al. 2003) , (Smith 1979) , (Nielsen 1989) . NRG-1 is expressed in the mid-trimester human fetal lung and increases in fetal lung at the onset of surfactant synthesis (Dammann et al. 2003) . NRG-1β increases proliferation in the adult type II cell line MLE12 cells and also stimulates the biosynthesis of disaturated phosphatidylcholine (DSPC) in these cells (Dammann et al. 2003) . However, it does not stimulate mitogenesis in primary fetal type II cell cultures. This may reflect a limitation of MLE12 cells as a model for the effects of NRG on fetal type II cells. Immunohistochemical studies show the presence of NRG-1β in fetal lung in mesenchymal cells underlying saccular epithelium and in airway epithelial cells before the late gestational onset of surfactant synthesis. Upon initiation of surfactant synthesis, NRG was visualized at the mesenchymal-epithelial cell border in saccular structures which implies paracrine involvement of NRG in lung cell differentiation (Dammann et al. 2003) .
Gamma secretase
The action of gamma secretase cleaves ErbB4 to release a soluble 4ICD fragment into the cytosol for transport to the nucleus (Goutte et al. 2002) , (Zhou and Carpenter. 2000) . Gamma secretase is an enzyme complex which consists of 4 components: Presenilin 1 (PSEN-1) or Presenilin 2 (PSEN-2), Nycastrin, anterior pharynx defective-1 (APH-1) and the PresenilinEnhancer 2. PSEN-1 or PSEN-2 are the active enzymatic component; the other components behave as scaffolding molecules and essential cofactors (Edbauer et al. 2003) , (Esler et al. 2002) , (Francis et al. 2002) . Studies using transgenic mice show that PSEN-1 and PSEN-2 have functionally distinct phenotypes in several organs including the lung (Mastrangelo et al. 2005) , (Lai et al. 2003) . While the pulmonary phenotypes have not been completely characterized, it is known that newborn mice with a PSEN-1 knockout have lungs with poorly developed saccular structures and undergo neonatal death with poorly expanded lungs. PSEN-2 knockout mice survive birth but develop progressive alveolar wall thickening, alveolar and airway fibrosis, and hemorrhage. Double knockouts show an exacerbation of the fetal/neonatal abnormalities of alveolar development (Mastrangelo et al. 2005) , (Lai et al. 2003) .
Recently, the authors used siRNA targeting PSEN-1 to more specifically define the importance of PSEN-1 and the sequential interactive relationship of PSEN-1 and TACE for ErbB4 processing controlling lung alveolar type II cell surfactant production (Fiaturi et al. 2014) . We found that ErbB4 signaling regulating surfactant synthesis in MLE-12 cells requires PSEN-1-dependent γ-secretase proteolysis. Our results emphasize the importance of PSEN-1 for ErbB4 signaling in control of alveolar type II cell differentiation. This work also introduced a novel and surprising insight into the mechanism of ErbB4 cleavage processing by showing that TACE activity is not a necessary antecedent for γ-secretase cleavage of ErbB4 in the control of surfactant DSPC synthesis and SP-B and SP-C expression (Fiaturi et al. 2014) . The dissociation of TACE and γ-secretase processing of ErbB4 may have an important translational impact as investigators seek to modulate ErbB4 signaling.
Despite the progress made in understanding NRG-ErbB4 signaling in developing lung, many important questions remain unanswered. Among these are:
What regulates PSEN1 expression in alveolar type II cells?
PSEN-1, an aspartyl protease that cleaves substrates within the cell membrane, is the catalytic subunit of the γ-secretase complex. Although PSEN-1 has been extensively studied in Alzheimer Disease studies, little is known about its regulation in lungs. The relationship between PSEN-1 function in such diverse pathophysiological settings may lead to important insights into mechanisms and pathogenesis of both Alzheimer Disease and surfactant synthesis.
What is the effect of ErbB4 isoforms lacking the γ-secretase cleavage site on surfactant proteins? ErbB 4 is known to produce functionally distinct isoforms as a result of alternative splicing. These include full-length isoforms that contain the TACE and γ-secretase cleavage sites, as well as isoforms that lack these cleavage sites. Future studies using type II epithelial cells from ErbB4 knock-out mice transfected with different isoforms and probed for the expression level for surfactant proteins and DSPC may well yield key mechanistic insights into the downstream signaling events.
What is the level of surfactant protein production and 4ICD release in the absence of tace?
Global inactivation of TACE through mutation of the zincdependent active sequence results in neonatal lethality and multiple organ developmental abnormalities, including dysplastic lung (Xu et al. 2013) . To further define the role of TACE in regulating lung development, lung epithelial and/or mesenchymal specific TACE conditional knockout mice have been generated (Xu et al. 2013) . These mice survived birth and showed abnormalities in lung saccularization but not in type II cell function. Although we dissociated presenilin-1 from TACE processing of ErbB4 in lung alveolar type II cell differentiation, the mechanistic action of nuclear ErbB4 in the developing lung remains unclear. Additional work clarifying Fig. 3 Neuregulin-ErbB4 signaling pathway. When NRG binds to ErbB4, two successive enzymatic cleavages occur. First TACE cleaves ErbB4 at the cell surfact (1), releasing the ectodomain. The second cleavage is carried out by gamma secretase (2) and releases the intracellular domain peptide called 4ICD. Next 4ICD binds to chaperone proteins (3) such as the YAP/14-3-3 complex that escort 4ICD into the nucleus where it binds to DNA (4) and regulates gene expression (5) the function of nuclear ErbB4 is necessary to establish the significance of this non-canonical signaling pathway.
Conclusion
In spite of advances in the treatment and prevention of RDS including the use of prenatal glucocorticoids and neonatal treatment with postnatal surfactant replacement, RDS remains one of the significant causes of morbidity and mortality in premature infants (Langston et al. 1984) , (Jobe et al. 1993) . Therefore, it is critical to understand the endogenous pathways regulating surfactant synthesis by type II cells in the developing alveolus. We and others have shown an important role of ErbB4 receptor and its ligand NRG in surfactant synthesis (Dammann et al. 2003) , ), (Liu et al. 2010) . We have dissociated TACE and γ-secretase processing of ErbB4 in lung type II cell surfactant production in neonatal mice, a model for the the developing lung in severely premature infants (Fiaturi et al. 2014) .
While these and other studies will reveal the molecular mechanisms regulating surfactant production in the developing lung, much more work is needed to provide a more complete understanding of the biology and pathophysiology of this signaling process. This, in turn, may lead eventually to clinical applications that will reduce or ameliorate the respiratory complications seen in premature infants.
